Paper: Sanofi bid for Piramal falters

Sanofi-Aventis' plans to buy a majority stake in India's Piramal Healthcare has fallen through because of a disagreement over valuation, sources familiar with the potential deal told the Economic Times. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.